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Purpose. To compare long-term patency of Heparin-Bonded Dacron (HBD) and Human Umbilical Vein (HUV) vascular
prostheses in above-knee femoro-popliteal bypass surgery.
Design. A prospective randomized multi-centre clinical trial.
Patients and methods. Femoro-popliteal bypasses were performed in 129 patients between 1996 and 2001. After random-
ization 70 patients received an HUV and 59 an HBD prosthesis. Patients were followed up every three months during the
first postoperative year and yearly thereafter. The median follow-up was 60 months (range 3e96 months). Graft occlusions
were detected by duplex scanning, angiography or surgical exploration.
Results. The cumulative primary patency rates were 79%, 66% and 58% at 1, 3 and 5 years postoperatively. Primary
patency rates for HUV were 74%, 64% and 58% at 1, 3 and 5 years and 84%, 68% and 58% for HBD, respectively
(log-rank test, p¼ 0.745). Overall secondary patency rates were 82%, 72% and 61% at 1, 3 and 5 years postoperatively.
The overall cumulative limb salvage at 5 years follow-up was 89% (CI 80%e91%) and was not dependent on graft type.
Smoking (p¼ 0.019), number of patent crural arteries (p¼ 0.030) and previous cerebro-vascular events (p¼ 0.030) were
significant predictors of graft occlusion.
Conclusion. There was no difference in long-term graft performance between HUV and HBD for above knee infrainguinal
bypass.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
Keywords: Peripheral arterial occlusive disease; Femoro-popliteal bypass; Peripheral bypass; Dacron; Heparin-bonded
polyester; Human umbilical vein; Claudication.Introduction
The choice of graft material for prosthetic femoro-
popliteal bypass has been a controversial matter over
the past decades. Many trials have been conducted to
investigate and compare graft adequacy for this proce-
dure.1 Despite the increasing evidence results are still
inconclusive.2 Therefore, the choice of graft often is
left to the surgeon’s preference.3
Presently, four grafts are available for femoro-
popliteal bypass: the autologous saphenous vein, poly-
tetrafluoroethylene (PTFE), double velour polyester
*Corresponding author. Dr. J. Adam van der Vliet, Department of
Vascular Surgery, Radboud University Medical Center Nijmegen,
690 Surgery POB 9101, 6500HB Nijmegen, The Netherlands.
E-mail address: j.vandervliet@chir.umcn.nl1078–5884/000061 + 07 $32.00/0  2007 Published by Elsevier Ltd o(Dacron) and Human Umbilical Vein (HUV).4 Saphe-
nous vein is considered the gold standard for bypass
whether the distal anastomosis is either above (AK)
or below the knee (BK).5 Prosthetic grafts are used rou-
tinely in the absence of the saphenous vein and are fea-
sible for AK distal anastomosis.6 Some argue that
patency rates for prosthetic grafts and saphenous
vein are equivalent in AK bypass for patients treated
by anticoagulant drugs. However, the general assump-
tion is that saphenous vein bypass has a lower risk of
graft failure.7 No explicit consensus exists on superior-
ity of any particular prosthetic graft. HUV is consid-
ered the most satisfactory and provides the best
long-term patency rates.8,9 However, previous reports
provide evidence that a prosthetic graft covered with
an antithrombotic farmacon, may be the preferred
graft for AK bypass.10,11n behalf of European Society for Vascular Surgery.
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A randomized, prospective, multi-center clinical trial
was performed comparing heparin-bonded collagen
coated polyester (Dacron, Intergard, Intervascular,
Inc., La Ciotat, France) and human umbilical vein
(Dardik, Biograft, Bio-Vascular, Inc., Saint-Paul, MN)
for femoro-popliteal bypass. Femoro-popliteal bypass
was defined as the insertion of a bypass graft with
the proximal anastomosis above the adductor canal
to the common-, profunda- or superficial femoral ar-
tery and distal to the popliteal artery AK or BK. The
standards for reporting lower extremity ischemia12
were implemented in this study. Critical limb ische-
mia was defined as ischemic rest pain and/or tissue
loss combined with an ankle pressure< 60 mmHg
with flat or barely palpable pulsations at the ankle
or metatarsals.
Sample size
This trial originally was designed to compare short-
term patency between both grafts. The initial power
analysis required a study population of 200 patients
to determine a significant difference in patency of
>10% at two years follow-up. Unfortunately, the
inclusion period provided only 129 patients, which
proved insufficient for short-term analysis. In order
to determine whether a five years follow-up evalua-
tion would be adequate, a second power analysis
based on the observed 1-year event rates of 0.24 and
0.14 in both groups was performed. In order to dem-
onstrate a 20% patency difference at 5 years with
a power of 80% two groups each with 66 patients
are required.
Patients
A femoro-popliteal bypass was performed in 129 pa-
tients between 1996 and 2001. Seventy patients were
randomized to HUV while 59 patients received HBD
prosthesis, even if the saphenous vein was adequate.
Preoperative workup included detailed evaluation of
patient history, cardiovascular risk factors, physical
examinations, standard treadmill walking tests and
calibrated angiography of the affected extremity.Eur J Vasc Endovasc Surg Vol 35, January 2008Male and female patients, aged 31e89, with dis-
abling intermittent claudication and an ankle/brachial
index (ABI) below 0.8 at rest were included in the pres-
ent study. All patients received elective femoro-
popliteal reconstruction for either occlusive arterial
disease or aneurysms of the superficial femoral- or
popliteal artery.
Patients younger than 30 - or older than 90 years of
age or patients with an ABI higher than 0.8 at rest
were excluded. Other exclusion criteria were: emer-
gency surgery for trauma, acute thrombosis or embo-
lism of the popliteal artery, the diagnosis or treatment
for malignancy within 12 months, hospital in-patient
treatment for cardiac failure in the previous six
months, the absence of the possibility for adequate
follow-up or contraindications for anticoagulant
drug therapy.
The trial patients also participated in the Dutch
BOA-trial,13 comparing the effect of coumarin deriva-
tives and acetylsalysilic acid after infra-inguinal by-
pass surgery. Cooperation was established with the
BOA-trial investigators to simplify randomization
and data collection for the mutual benefit of both
studies. The present study was approved by the local
Institutional Review Board and fully informed con-
sent, given in writing, was obtained from all patients.
The grafts
The Dacron prosthesis consists of double velour poly-
ester with a reversed locknit construction. The graft is
coated with heparin on its inner surface and type I
collagen on the outer surface. The Human Umbilical
Vein is glutaraldehyde tanned and surrounded by
a tightly knitted Dacron mesh.
Currently, both prostheses are used for femoro-
popliteal bypass.14 The HUV graft only may be used
in accordance to renewed European Union guidelines.
These demand a confirmed exclusion of HIV contam-
ination of the original human umbilical blood (EC
Treaty, article 250, Brussels, 2003).
Randomization and follow-up
Randomization was controlled by the BOA-trial
agency using a dedicated computer program. The
graft type for femoro-popliteal reconstruction was
determined at least 24 hours prior to surgery. All
patients were treated with heparin peri-operatively.
Post-operatively, patients were randomized to life-
long treatment with either acetylsalysilic acid
(Aspirin) 80 mg daily or coumarin derivates (Sintrom)
[target INR ratio 3.0e4.5], in accordance to local
63Umbilical Vein vs Dacron in Fem-pop Bypasstreatment protocols. Patient follow-up visits were at 3
monthly intervals during the first postoperative year
and yearly thereafter.
Endpoints and patency evaluation
Graft patency was determined at follow-up visits, as-
sessed at yearly intervals and stratified by graft material
and type of anticoagulant medication. Palpable graft
pulsations combined with definite distal pulses were
considered evidence for an open lumen. Graft occlusions
were detected by angiography, duplex scanning or oper-
ative exploration. Patency was categorized as follows:
- Primary patency; the time from implantation of
the graft to primary occlusion without adjunctive
measures, marking the primary endpoint.
- Primary assisted patency; the time from implanta-
tion to primary graft occlusion achieved by adjunc-
tive measures to maintain graft patency.
- Secondary patency; the time after restoring patency
by an intervention such as thrombectomy, throm-
bolysis or percutaneous transluminal angioplasty.
The secondary endpoint was marked by final graft
occlusion, graft removal or amputation of a limb.
Statistical analysis
The trial was conducted on an ‘intention to treat’ basis.
Once entered a patient was not withdrawn or ex-
cluded from this analysis. Graft patency, limb salvage
and mortality were assessed by the Kaplan-Meier sur-
vival model. The difference in patency between both
grafts was analyzed statistically by the log rank test.
The influence of various risk factors on patency was
examined by the Cox regression analyses.
Results
Patient cohorts
Patient enrollment and allocation is outlined in Fig. 1.
Eight patients received an autologous saphenous vein
bypass and consequently were excluded from analy-
sis. The risk factors in HUV and HBD groups were
similar (Table 1). The common femoral artery was
used for proximal anastomosis in 126 procedures
(98%). The distal anastomosis was AK popliteal in
122 cases (95%), BK popliteal in 4 (3%) and to the
tibioperoneal trunk in 3 (2%) patients. Postoperatively,
median AB-indices increased from 0.56 (0.16e0.80) to
0.9 (0.22e1.1) for HUV and from 0.60 (0.19e0.80) to 1.0(0.27e1.3) for HBD. Median postoperative Rutherford
classifications were 0 (0e6) for HUV and 0 (0e5) for
HBD. Postoperative anti-coagulant drug treatment
was equally distributed between both groups. Cou-
marin derivates were prescribed to 68 patients
(53%); HUV 36 and HBD 32. Sixty-one patients (47%)
were treated with acetylsalysilic acid; HUV 34 and
HBD 27. Median hospital stay was 10 days (4e109)
for HUV and 11.5 (6e30) for HBD grafts. Twelve
patients (9%) were lost to follow-up. Median follow-
up was 60 months (range 3e96 months).
Morbidity and mortality
Thirteen patients (10%) died during follow-up, 9
(13%) in the HUV group and 4 (7%) in the HBD
group. Grafts were patent to the time of death in 12
of these patients (HUV 8, HBD 4). Two patients died
within 30 days after the operation, accounting for
2% operative mortality. Cumulative survival was
92%, 90% and 87% at 1, 3 and 5 years follow-up.
A total of 43 complications was reported in 40 pa-
tients (31%) with 18 (26%) in the HUV group and 25
(42%) for HBD. Complications were postoperative
bleeding (3%), graft infection (3%), cardiac events (4%)
and wound morbidity (18%). The incidence of graft in-
fection did not differ between groups, with 2 cases
in each. Re-operation was required in 7 patients (10%)
in the HUV- and 5 patients (8%) in the HBD group.
Graft performance
Overall primary patency rates were 79%, 66% and
58% at 1, 3 and 5 years postoperatively. Primary pa-
tency rates for HUV were 74%, 64% and 58% at 1, 3
and 5 years and 84%, 68% and 58% for HBD, respec-
tively (log-rank test, p¼ 0.745) (Fig. 2 and Table 2).
Primary patency rates at 5 years in the HUV group
were 55% for patients on acetylsalysilic acid and
48% for patients on coumarin medication (log-rank
test p¼ 0.406). In the HBD group these rates were
47% and 62%, respectively (log-rank test p¼ 0.362).
An overall analysis of all four subgroups showed no
differences (log-rank test p¼ 0.428).
PTA was performed in 3 patients to prevent pri-
mary graft occlusion. Therefore, primary assisted
patency rates were almost identical to the primary
patency rates.
We were able to restore patency in 32 of the 50 pri-
mary graft occlusions (64%), 18 for HUV and 14 for
HBD. Long-term (5 yr) patency was achieved in only
9 patients. Surgical thrombectomy was required in
21 patients (16%) and resulted in long-term patencyEur J Vasc Endovasc Surg Vol 35, January 2008
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Fig. 1. Study flow chart.for 6 patients. Eleven patients (9%) underwent throm-
bolysis, successfully maintaining graft patency in 3
cases. The graft was replaced in 10 patients (8%),
who were excluded from further analyses. Eight pa-
tients (6%) received conservative treatment. Overall
secondary patency rates were 82%, 72% and 61% at
1, 3 and 5 years postoperatively. Secondary patency
rates were 78%, 71% and 60% for HUV grafts and
85% and 73% and 61% for HBD grafts at 1, 3 and 5
years respectively (log-rank test, p¼ 0.602).
Limb salvage
Major amputation was required in 11 patients (9%).
Six amputations were performed after HUV bypass
(9%) and 5 after HBD implantation (8%). Pre-operative
median Rutherford classification for limb loss patients
was 4 (range 3e5), indicating critical ischemia. No
amputations were performed in patients withEur J Vasc Endovasc Surg Vol 35, January 2008intermittent claudication. Six amputations (5%) were
performed as a secondary intervention after primary
graft occlusion. Overall cumulative limb salvage at
5 years follow-up was 89%. Limb salvage for HUV
was 87% and 90% for HBD.
Risk factors
Cardiovascular risk factors were assessed during
patient work-up and included: diabetes mellitus,
smoking history, hyperlipidemia, angina pectoris,
myocardial infarction, cerebro-vascular events, hyper-
tension and hyperhomocysteinemia. The influence on
graft occlusion of critical limb ischemia, choice of an-
ticoagulant drug treatment, graft material, gender,
age and the number of patent crural arteries also
were assessed. The mean number of patent crural
arteries was 1.6 for patients who suffered graft occlu-
sion and 2.3 for patients with a patent graft at 5 years
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tially important co-variables determined smoking
(p¼ 0.019), the number of patent crural arteries
(p¼ 0.030) and previous cerebro-vascular events
(p¼ 0.030) as significant predictors of graft occlusion.
Graft material was a non-significant predictor
(p¼ 0.293).
Table 1. Patient characteristics
Parameter HUV HBD
n 70 59
Age (y), median (range) 65 (41e88) 65 (36e84)
Gender (%)
- Male 52 (74%) 35 (59%)
Co-morbidity (%)
- DM 23 (33%) 21 (36%)
- Smoking 47 (67%) 43 (73%)
- Hyperlipedemia 21 (30%) 26 (44%)
- Angina/MI 20 (29%) 16 (27%)
- Cerebrovascular events 12 (17%) 4 (7%)
- Hypertension 34 (49%) 29 (49%)
- Homocysteinemia 2 (3%) 2 (3%)
Rutherford classification,
median (range)
3 (1e6) 3 (2e5)
Critical limb ischemia (%) 27 (39%) 18 (30%)
Tissue loss (%) 12 (17%) 9 (15%)
ABI preoperative,
median (range)




Supragenicular bypass (%) 65 (93%) 57 (97%)
Days hospital stay,
median (range)
10 (4e109) 11.5 (6e30)
DM: Diabetes Mellitus, MI: Myocardial Infarction, CVA: Cerebro
Vascular Accident.
No statistical differences were detected between groups (p¼ ns).
Fig. 2. Kaplan-Meier analysis of primary patency rates for
HUV and HBD groups.Discussion
In the early 1970s, the use of polyester fibre (Dacron)
as prosthetic bypass graft material for infrainguinal
arterial reconstructions was abandoned since autolo-
gous vein bypass grafting achieved better results.7 Su-
perior saphenous vein patency rates were attributed
to the fact that any prosthetic graft surface has a higher
grade of thrombogenicity than graft material with
a genuine endothelial lining. Prosthetic grafts other
than polyester mainly consisted of polytetrafluoro-
ethylene (PTFE) or human umbilical vein graft mate-
rial (HUV). Other factors that have been identified
to influence the outcome of bypass grafting are distal
anastomotic level, diabetic disease, the continuation
of tobacco use and the dimension of distal run-
off.15,16 Carefully randomized controlled trials show-
ing the benefit of the use of antithrombotic medication
later redirected interest towards the use of polyester
bypass grafts. In the mean time, modifications of the
prosthetic fabric and thus, the graft surface, were
made in order to reduce thrombogenicity.12,17,18
An obvious approach to the development of a vas-
cular prosthesis is a graft that closely resembles a nat-
ural blood vessel in both composition and mechanical
characteristics.19 In the absence of a suitable autolo-
gous vein graft, the concept of human umbilical
vein (HUV) grafts serves as an alternative to a conduit
with a genuine intimal layer. It consisted of glutaral-
dehyde stabilized human umbilical vein in its original
form. Presumably because of mechanical fatigue
through the lack of stability of collagen cross-links,
it was prone to long-term degradation, dilation, and
frank aneurysm formation. To counter this possible
disadvantage, a polyester mesh cover was introduced,
which unfortunately decreased handling quality. The
concerns regarding biodegradation and aneurysm for-
mation were never truly scientifically founded.20
When implanted, the luminal surface of a prosthetic
graft, on exposure to a high blood flow, immediately is
coated with a layer of coagulation proteins, mainly con-
sisting of fibrin. Heparin coverage of the graft surface
may aid in disrupting the coagulation cascade and there-
fore reduce the intrinsic thrombogenicity of the graft.13
Table 2. Numbers of patients (n[ 129) at risk in Kaplan-Meier
analysis of Fig. 2







66 D. M. Scharn et al.After formation, the fibrin layer becomes organized
by ingrowth of myofibroblasts arising from the blood-
stream and most importantly, from ingrowth through
the interstices of the graft wall. This ‘pseudointimal’
layer is of utmost importance, because its thickness
influences luminal diameter and thus, the passage of
blood. This is a particular issue for small diameter con-
duits on distal and therefore smaller vessels.21,22 It was
thought, that the process of formation and amount of
a ‘neointima’ could be influenced by changing the inter-
nal surface of the graft material through the use of graft
flow-surface modifications and treatment with antith-
rombotic or anti-proliferative agents. The choice of hep-
arin as a supplement to the graft is based on the
rationale that it both prevents thrombosis via inhibition
of thrombin and activated clotting factors IX, X, XI and
XII, and it reduces intimal hyperplasia through antipro-
liferative effects on smooth muscle cells.23 Its ability
to reduce intimal hyperplasia has been investigated
both in animal studies and in clinical practice.24,25
Therefore, heparin has been incorporated into a wide
range of medical devices from haemodialysis filters to
vascular stents and grafts. As heparin has a strong an-
ionic character, ionic bonding is achieved on surfaces
pre-treated with cationic substances. A general disad-
vantage of this method, however, is the rapid release
of heparin upon exposure to blood or plasma. This
may be overcome by the co-polymerization of surfaces
with substances carrying a positive charge. Quaternary
ammonium salts with hydrophobic tails, such as trido-
decylmethylammonium chloride (TDMAC), have
found wide application in this role. In the manufacture
of the heparin-bonded graft used in this study the
heparin is bound to the luminal surface of the graft as
a complex with TDMAC.8
Johnson and co-workers3 performed a large, pro-
spective randomized trial reporting 73%, 53% and
39% patency rates for saphenous vein, HUV and
PTFE at five years follow-up, respectively. Possibly,
a higher rate of early bypass graft thromboses and
major amputations within the first 30 days in the
HUV group (12.3% for HUV vs. 6.1% for PTFE) com-
bined with the higher technical requirements and
costs explain the selection of PTFE by many surgeons
at the time. Multiple studies have confirmed the supe-
rior long-term patency rate for saphenous vein over
HUV and for HUV over PTFE.8,9,26,27 Additionally,
Post and co-workers suggested that PTFE and Dacron
were equally suitable for femoro-popliteal bypass,28
whereas Jensen and co-workers stated that Dacron
might even be superior to PTFE.29 Devine and co-
workers10 found significantly better patency rates for
HBD (59%) compared to PTFE (49%) at three years
follow-up. This trial also suggests a higher incidenceEur J Vasc Endovasc Surg Vol 35, January 2008of limb amputation in the PTFE group at five years
follow-up.
Primary and secondary patency rates of femoro-
popliteal bypasses did not differ between HUV and
HBD in our study. The observed patency rates
compared favourably with other studies. Systematic
reviews of category A and B randomized trials report
no evidence for the preferred use of Dacron, PTFE, or
HUV grafts in the femoropoliteal area.4 In some stud-
ies, different patency rates exist between HUV and
PTFE in relation to the time after surgery: Johnson
and Lee8 state that there is a small advantage for
PTFE in the short-term compared to HUV grafts.
Our study did not indicate a difference in secondary
patency rates at 1, 3 or 5 years follow-up.
Most of the patients in this study also participated
in the Dutch BOA trial investigating the effect of post-
operative anticoagulant medical treatment on bypass
graft patency, which might be a possible source of
bias. Tangelder and co-workers12 concluded that ace-
tylsalysilic acid significantly reduced non-venous
graft occlusion, although the absolute difference was
small. Participation in the BOA-trial did not interfere
with the present study because patients were random-
ized to either coumarin derivates or acetylsalysilic
acid. Thus, the possible benefit of acetylsalysilic acid
medication was equal in both groups. Moreover, our
analyses did not reveal an influence of anticoagulant
medication on primary graft patency.
Our results suggest that HBD is an acceptable alter-
native for HUV in femoro-popliteal bypass surgery.
There is no reason to assume that a significant differ-
ence in primary or secondary patency exists between
grafts. HUV grafts did not suffer from higher early
failure rates than HBD grafts.
Femoro-popliteal bypass surgery cannot be per-
formed with one single, suitable graft for every situa-
tion. The choice of an arterial substitute depends upon
many factors.30 Superficial femoral artery disease thus
presents a complex challenge for therapy while at the
same time, the surgical armamentarium is rapidly ex-
panding.31 Sophisticated treatment options, including
endovascular techniques, are still being refined but
until endovascular techniques have been subjected
to rigorous comparison with conventional bypass sur-
gery, bypass surgery will continue to have an impor-
tant role in vascular surgery.
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